Use of Enteric-Coated Mycophenolate Sodium in De Novo Renal Transplant Recipients With High Incidence of Delayed Graft Function

Transplantation Proceedings

Volumn 38, Issue 3, 2006, Pages 905-908

  Schlavelli, R ^a   Gaite, L ^b   Agost Carreno C ^c   Baran, M ^d   Novoa, P ^e   Massari, P ^e   Otero, A B ^f   Piulats, E ^g  

^a HOSPITAL GENERAL DE AGUDOS DR COSME ARGERICH   (Argentina)

^b Clinica de Urologia y Nefrologia   (Argentina)

^c Sanatorio Mitre   (Argentina)

^d CRAI Sur   (Argentina)

^e HOSPITAL PRIVADO   (Argentina)

^f Hospital Privado de Córdoba ^*  (Argentina)

^g HOSPITAL ESPAÑOL   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; CREATININE; CYCLOSPORIN; MYCOPHENOLIC ACID; STEROID;

ABDOMINAL PAIN; ACUTE GRAFT REJECTION; ADULT; ANEMIA; ARTICLE; BACTERIAL PNEUMONIA; CADAVER KIDNEY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENTERIC COATED TABLET; FEMALE; GASTROINTESTINAL SYMPTOM; HIGH RISK PATIENT; HLA MATCHING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; ISCHEMIA; KIDNEY BIOPSY; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVING DONOR; MALE; MICROEMULSION; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; RECIPIENT; RENAL GRAFT DYSFUNCTION; SURVIVAL; THROMBOCYTOPENIA; TREATMENT OUTCOME; URINARY TRACT INFECTION; VOMITING;

ADULT; CYCLOSPORINE; EMULSIONS; FEMALE; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; TABLETS, ENTERIC-COATED;

EID: 33646075974     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2006.02.047     Document Type: Article

References (22)

1. Allison A.C., and Eugui E.M. Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF). Clin Transplant 10 (1996) 77
2. Meier-Kriesche H.U., Ojo A.O., Leichtman A.B., et al. Effect of mycophenolate mofetil on long-term outcomes in African American renal transplant recipients. J Am Soc Nephrol 11 (2000) 2366
3. Meier-Kriesche H.U., Steffen B.J., Hochberg A.M., et al. Mycophenolate mofetil versus azathioprine therapy is associated with a significant protection against long-term renal allograft function deterioration. Transplantation 75 (2003) 1341
4. Pelletier R.P., Akin B., Henry M.L., et al. The impact of mycophenolate mofetil dosing patterns on clinical outcome after renal transplantation. Clin Transplant 17 (2003) 200
5. Salvadori M., Holzer H., de M.A., et al. Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in the novo renal transplant patients. Am J Transplant 4 (2004) 231
6. Daly P.J., Power R.E., Healy D.A., et al. Delayed graft function. a dilemma in renal transplantation. BJU Int 96 (2005) 498
7. Ojo A.O., Wolfe R.A., Held P.J., et al. Delayed graft function. risk factors and implications for renal allograft survival. Transplantation 63 (1997) 968
8. Ojo A.O., Meier-Kriesche H.U., Hanson J.A., et al. Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation 63 (2000) 2239
9. Bunnapradist S., and Takemoto S.K. Multivariate analysis of antibody induction therapy and their associated outcomes in deceased donor transplants. Transplant Proc 37 (2005) 889
10. Hariharian A., Morawski K., Sillix D.H., et al. induction therapy with basillximab versus Thymoglobulin in African-American kidney transplant recipients. Transplantation 79 (2005) 716
11. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 61 (1996) 1029
12. Hardinger K.L., Brennan D.C., Lowell J., et al. Long-term outcome of gastrointestinal complications in renal transplant patients treated with mycophenolate mofetil. Transplant Int 17 (2004) 609
13. Schnitzier M.A., Hardinger K.L., Burroughs T.E., et al. Consequences of immunosuppression minimization following diagnosis of gastrointestinal complications in renal transplant (2005), American Transplant Congress, wash, USA
14. Schmouder R., Arns W., Merkel F., et al. PK of ERL080. a new enteric coated formulation of mycophenolic acid sodium. AST 18th Annual Meeting US (1999)
15. Budde K., Glander P., Hahn U., et al. Pharmacokinetic and pharmacodynamic comparison of mycophenolate mofetil and enteric-coated mycophenolate sodium in maintenance transplant patients. Am J Transplant 2 (2002) 399
16. Abbud-Filho M., Girón F., Hernández E., et al. Maintenance renal transplant recipients can be safely converted from MMF to enteric-coated mycophenolate sodium tablets. interim results of a multicenter Latin American study. Transplant Proc 36 (2004) 1647
17. Massari P., Duro-Garcia V., Giron F., et al. Safety assessment of the conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in stable renal transplant recipients. Transplant Proc 36 (2005) 916
18. Abbud-Filho M., Massari P., Giron F., et al. Conversion from mycophenolate mofetil (MMF) to enteric coated mycophenolate sodium (EC-MPS, myfortic®) on an equimolar or higher than equimolar basis. comparative analysis of safety and tolerability variables (2005), ESOT, Geneve
19. Thervet E., Preffer F., Scolari M.P., et al. Clinical outcomes during the first three months post transplant in renal allograft recipients managed by C2 monitoring of cyclosporine microemulsion. Transplantation 76 (2003) 903
20. Mendez R., Light J., Pearson T.C., et al. Neoral® therapy optimized by C2 monitoring and Simulect® induction can result in a low acute rejection rate in renal transplant recipients (2004) ATC Boston; Abs 355
21. Mourad G., Rostaing L., Legendre C., et al. Assessment of two strategies of neoral administration, early versus delayed, on renal function and efficacy in de novo renal transplant patients receiving myfortic, steroids, and anti-IL2R antibodies. 12-month results of a randomized, multicentre, open, prospective controlled study. Transplant Proc 37 (2005) 920
22. Hale M.D., Nicholls A.J., Bullingham R.E., et al. The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Clin Pharmacol Ther 64 (1998) 672